SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Bergström Anders) ;pers:(Bergström Stefan)"

Sökning: WFRF:(Bergström Anders) > Bergström Stefan

  • Resultat 1-10 av 14
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  • Ekman, Simon, et al. (författare)
  • Clinical value of using serological cytokeratins as therapeutic markers in thoracic malignancies
  • 2007
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 27:5B, s. 3545-3553
  • Forskningsöversikt (refereegranskat)abstract
    • In recent years, there has been an increasing awareness among physicians of the value of therapeutic interventions in patients suffering from lung cancer and mesothelioma. A search for an optimal approach using surgery, irradiation and chemotherapy in different settings of the tumour disease, including curatively aimed adjuvant chemotherapy after locoregional surgery or radiotherapy, has resulted in gradually improved survival rates. Still, early detection is crucial if there is to be a possibility of curing patients or prolonging life in cases of relapsed disease. Several studies have been initiated in which surrogate markers are evaluated in comparison to chest X-rays and computer tomography. The present review focuses on the predictive and prognostic value of using serological cytokeratins as tumour markers for patients suffering from thoracic malignancies.
  •  
4.
  • Holgersson, Georg, et al. (författare)
  • [In Process Citation].
  • 2015
  • Ingår i: Läkartidningen. - 0023-7205 .- 1652-7518. ; 112
  • Tidskriftsartikel (refereegranskat)abstract
    • The work-up process for lung cancer patients consists of several steps from suspicion of malignant disease to start of treatment. Delays between these steps should be minimized. Data in the Swedish National Lung Cancer Register show that the work-up times for lung cancer patients vary greatly between different counties in central Sweden. In order to reduce delays, a trial of implementing patient guides (Sw: patientlotsar) for patients referred to the hospital was conducted. When comparing the work-up times before and after implementation of patient guides the median waiting time from suspicion of lung cancer to start of treatment in the region was reduced from 71 to 45 days. Furthermore, the duration of most of the steps in the work-up process were shortened despite more complex investigation procedures, e.g. increased use of PET/CT in the guided patient group.
  •  
5.
  • Holgersson, Georg, et al. (författare)
  • The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy
  • 2017
  • Ingår i: Neoplasma (Bratislava). - Bratislava : AEPress. - 0028-2685 .- 1338-4317. ; 64:6, s. 909-915
  • Tidskriftsartikel (refereegranskat)abstract
    • Chemoradiotherapy is the standard of care for inoperable stage III non-small cell lung cancer (NSCLC). This treatment, however, offers only a small chance of cure and is associated with many side effects. Little research has been made concerning which patients benefit most/least from the treatment. The present study evaluates the prognostic value of anemia, leukocytosis and thrombocytosis at diagnosis in this treatment setting. In the present study, data were collected retrospectively for 222 patients from two different phase II studies conducted between 2002-2007 in Sweden with patients treated with chemoradiotherapy for stage IIIA-IIIB NSCLC. Clinical data and the serum values of hemoglobin (Hgb), White blood cells (WBC) and Platelets (Plt) at enrollment were collected for all patients and studied in relation to overall survival using Kaplan-Meier product-limit estimates and a multivariate Cox proportional hazards regression model. The results showed that patients with thrombocytosis (Plt > 350 x 109 /L) had a shorter median overall survival (14.5 months) than patients with normal Plt at baseline (23.7 months). Patients with leukocytosis (WBC > 9 x 109 /L) had a shorter median survival (14.9 months) than patients with a normal WBC at baseline (22.5 months). However, in a multivariate model including all lab parameters and clinical factors, only thrombocytosis and performance status displayed a prognostic significance. In Conclusion, thrombocytosis showed to be an independent prognostic marker associated with shorter overall survival in stage III NSCLC treated with curatively intended chemoradiotherapy. This knowledge can potentially be used together with established prognostic factors, such as performance status when choosing the optimal therapy for the individual patient in this clinical setting
  •  
6.
  • Nilsson, Jonas, et al. (författare)
  • The role of comorbidity in the management and prognosis in nonsmall cell lung cancer : a population-based study
  • 2017
  • Ingår i: Acta Oncologica. - : TAYLOR & FRANCIS LTD. - 0284-186X .- 1651-226X. ; 12:11, s. S1985-S1986
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Coexisting disease constitutes a challenge for the provision of optimal cancer care. The influence of comorbidity on lung cancer management and prognosis remains incompletely understood. We assessed the influence of comorbidity on treatment intensity and prognosis in a population-based setting in patients with nonsmall cell lung cancer.Material and methods: Our study was based on information available in Lung Cancer Data Base Sweden (LcBaSe), a database generated by record linkage between the National Lung Cancer Register (NLCR) and several other population-based registers in Sweden. The NLCR includes data on clinical characteristics on 95% of all patients with lung cancer in Sweden since 2002. Comorbidity was assessed using the Charlson Comorbidity Index. Logistic regression and time to event analysis was used to address the association between comorbidity and treatment and prognosis.Results: In adjusted analyses encompassing 19,587 patients with a NSCLC diagnosis and WHO Performance Status 0-2 between 2002 and 2011, those with stage-IA-IIB disease and severe comorbidity were less likely to be offered surgery (OR: 0.45; 95% CI: 0.36-0.57). In late-stage disease (IIIB-IV), severe comorbidity was also associated with lower chemotherapy treatment intensity (OR: 0.76; 95% CI: 0.65-0.89). In patients with early, but not late-stage disease, severe comorbidity in adjusted analyses was associated with an increased all-cause mortality, while lung cancer-specific mortality was largely unaffected by comorbidity burden.Conclusions: Comorbidity contributes to the poor prognosis in NSCLC patients. Routinely published lung cancer survival statistics not considering coexisting disease conveys a too pessimistic picture of prognosis. Optimized management of comorbid conditions pre- and post-NSCLC-specific treatment is likely to improve outcomes.
  •  
7.
  • Wennerberg, Johan, et al. (författare)
  • Results from a prospective, randomised study on (accelerated) preoperative versus (conventional) postoperative radiotherapy in treatment of patients with resectable squamous cell carcinoma of the oral cavity : The ARTSCAN 2 study
  • 2022
  • Ingår i: Radiotherapy and Oncology. - : Elsevier. - 0167-8140 .- 1879-0887. ; 166, s. 26-32
  • Tidskriftsartikel (refereegranskat)abstract
    • Background and purposeAn earlier prospective randomised multicentre study (ARTSCAN) in head and neck cancer patients that compared conventionally fractionated radiotherapy (CF) with accelerated radiotherapy (AF) was inconclusive. In the subgroup of oral cavity squamous cell cancer (OCSCC) a large absolute, but not statistically significant, difference in local control was seen in favour of AF. This difference was more pronounced in resectable tumours. The finding raised the hypothesis that AF could be beneficial for OCSCC patients. In addition, the longstanding controversy on pre- or postoperative radiotherapy was addressed.Materials and methodsPatients with OCSCC, judged to withstand and likely benefit from combined therapy, were recruited. Subjects were randomised to either preoperative AF with 43 fractions given as a concomitant boost with two fractions/day to the tumour bearing volume to a total dose of 68 Gy in 4.5 weeks followed by surgery, or primary surgery with postoperative CF, total dose 60 or 66 Gy in 6–7 weeks. For patients whose tumours had high-risk features, 66 Gy and concomitant cisplatin was prescribed.Results250 patients were randomised. Median follow-up was 5 years for locoregional control (LRC) and 9 years for overall survival (OS). There were no statistically significant differences between the two treatment arms regarding LRC and OS. LRC at five years was 73% (95% CI, 65–82) in preoperative AF and 78% (95% CI, 70–85) in postoperative CF.Toxicity was more pronounced in preoperative AF.ConclusionThis study does not support that AF prior to surgery improves outcome in oral cavity cancer compared with postoperative CF.
  •  
8.
  • Willén, Linda, 1979-, et al. (författare)
  • Are older patients with non-small cell lung cancer receiving optimal care? A population-based study
  • 2022
  • Ingår i: Acta Oncologica. - : Taylor & Francis. - 0284-186X .- 1651-226X. ; 61:3, s. 309-317
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Results from studies addressing age-related patterns of cancer care have found evidence of unjustified differences in management between younger and older patients.Methods: We examined associations between age and clinical presentation, management and mortality in patients diagnosed with non-small cell lung cancer (NSCLC) between 2002 and 2016. Analyses were adjusted for comorbidity and other factors that may have affected management decisions and outcomes.Results: The study population encompassed 40,026 patients with NSCLC. Stage at diagnosis did not differ between age groups ≤ 84. The diagnostic intensity was similar in age groups <80 years. In patients with stage IA–IIB disease and PS 0–2, surgery was more common in the youngest age groups and decreased with increasing age, and was rarely performed in those ≥ 85 years. The use of stereotactic body radiotherapy (SBRT) increased with age (≤69 years 5.4%; ≥85 years 35.8%). In patients with stage IIIA disease and PS 0–2, concurrent chemoradiotherapy was more common in younger patients (≤69 years 55.3%; ≥85 years 2.2%). In stage IA–IIIA disease, no major differences in treatment-related mortality was observed. In stage IIIB–IV and PS 0–2, chemotherapy was more common in patients <80 years. However, 58.1% of patients 80–84 years and 30.3% ≥ 85 years received treatment. In stage IA–IIIA, overall and cause-specific survival decreased with increasing age. No age-differences in survival were observed in patients with stage IIIB-IV NSCLC.Conclusion: Treatments were readily given to older patients with metastatic disease, but to a lesser degree to those with early stage disease. Significant differences in cause specific survival were observed in early, but not late stage disease. Our findings underscore the importance of individualized assessment of health status and life expectancy. Our results indicate that older patients with early stage lung cancer to a higher extent should be considered for curative treatment.
  •  
9.
  • Willén, Linda, 1979-, et al. (författare)
  • Depression, anxiety, intoxication and suicide following a diagnosis of non-small cell lung cancer : A population-based study (Sweden)
  • Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
    • Introduction: Cancer affects quality of life, including psychological wellbeing. The risk of depression and suicide have been found to be increased in cancer patients, especially in cancers with poor prognosis. The aim of this study was to examine rates of indicators of psychological distress in patients with non-small cell lung cancer (NSCLC). Methods: We used data in a population-based research database to assess post-diagnostic events of depression, anxiety, intoxication (alcohol, opioids, sedatives and hypnotics) and suicide in patients with non-small cell lung cancer (NSCLC) in comparison to individuals free of lung cancer (comparators) matched on age, sex and area of residence, representing the background population. Results: The study population encompassed 38,454 patients diagnosed with NSCLC between 2002 and 2016 and 184,090 lung cancer free individuals. Compared to the comparators, patients with NSCLC were more likely to have an immigrant background (14.9 % vs 12.6 %), a lower educational level (42.9 % vs 36.7 %) and a higher comorbidity burden (28.3 % vs 16.4 %). Post diagnostic rates of depression, anxiety intoxication and suicide were higher in NSCLC patients compared to individuals free of lung cancer. While the risk of depression, anxiety and suicide decreased over time, the risk of intoxication remained elevated throughout the follow-up period.  Conclusion: We found evidence of increased rates of indicators of psychological distress after a diagnosis of NSCLC. Our findings underscore the importance of symptom monitoring post-diagnosis and preparedness to provide adequate support and treatment.
  •  
10.
  • Willén, Linda, 1979-, et al. (författare)
  • Educational level and management and outcomes in non-small cell lung cancer. A nationwide population-based study
  • 2019
  • Ingår i: Lung Cancer. - : ELSEVIER IRELAND LTD. - 0169-5002 .- 1872-8332. ; 131, s. 40-46
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives: We examined associations between educational level and clinical presentation, patterns of management and mortality in patients with non-small cell lung cancer (NSCLC) in Sweden, a country with a National Health Care System. Materials and Methods: We identified 39,671 patients with a NSCLC diagnosis 2002-2016 in Lung Cancer Data Base Sweden (LCBaSe), a population-based research database. In analyses adjusted for comorbidity and other prognostic factors, odds Ratios (OR) and hazard Ratios (HR) were estimated to examine associations between patients' educational level and aspects of management and mortality. Results: Stage at diagnosis and waiting times did not differ between educational groups. In multivariable analysis, the likelihood to undergo PET/CT and assessment in a multidisciplinary team setting were higher in patients with high compared to low education (aOR 1.14; CI 1.05-1.23 and aOR 1.22; CI 1.14-1.32, respectively). In patients with early stage IA-IIB disease, the likelihood to undergo stereotactic radiotherapy was elevated in patients with high education (aOR 1.40; CI 1.03-1.91). Both all-cause (aHR 0.86; CI 0.77-0.92) and cause specific mortality (aHR 0.83; CI 0.74-0.92) was lower in patients with high compared to low education in early stage disease (IA-IIB). In higher stage NSCLC no differences were observed. Patterns were similar in separate assessments stratified by sex and histopathology. Conclusions: While stage at diagnosis and waiting times did not differ between educational groups, we found socioeconomic differences in diagnostic intensity, multidisciplinary team assessment, stereotactic radiotherapy and mortality in patients with NSCLC. These findings may in part reflect social gradients in implementation and use of novel diagnostic and treatment modalities. Our findings underscore the need for improved adherence to national guidelines.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 14
Typ av publikation
tidskriftsartikel (12)
annan publikation (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (11)
övrigt vetenskapligt/konstnärligt (3)
Författare/redaktör
Bergqvist, Michael (13)
Lambe, Mats (9)
Berglund, Anders (9)
Wagenius, Gunnar (9)
Willén, Linda, 1979- (7)
visa fler...
Isaksson, Johan (6)
Larsson, Anders (3)
Hesselius, Patrik (2)
Ekman, Simon (2)
Henriksson, Roger (2)
Brattström, Daniel (2)
Holgersson, Georg (2)
Dreilich, Martin (2)
Johansson, Peter (1)
Wennerberg, Johan (1)
Zackrisson, Björn (1)
Gebre-Medhin, Maria (1)
Farnebo, Lovisa, 197 ... (1)
Sjödin, Helena (1)
Ekberg, Tomas (1)
Kjellén, Elisabeth (1)
Nilsson, Per (1)
Brun, Eva (1)
Koyi, Hirsh (1)
Hallqvist, Anders (1)
Liv, Per, 1979- (1)
Nilsson, Jonas (1)
Reizenstein, Johan (1)
Eriksson, Peter (1)
Söderkvist, Karin (1)
Gullbo, Joachim (1)
Nilsson, R. Jonas A. (1)
Wahlgren, Magnus (1)
Kristiansson, Stefan (1)
Cederblad, Lena (1)
Högmo, Anders (1)
Goike, Helena (1)
Wickart-Johansson, G ... (1)
Nyman, Jan (1)
Hammarstedt-Nordenva ... (1)
Löden, Britta (1)
Willén, Linda (1)
Carlwig, Kristin (1)
Rzpecki, Jan (1)
Ojdahl-Boden, Anna (1)
Öjdahl-Boden, Anna (1)
visa färre...
Lärosäte
Umeå universitet (10)
Uppsala universitet (10)
Karolinska Institutet (7)
Linköpings universitet (1)
Lunds universitet (1)
Språk
Engelska (11)
Svenska (2)
Odefinierat språk (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (12)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy